Safety and Efficacy of the OmniaSecure Defibrillation Lead: Final Results From LEADR
Authors, Journal, Affiliations, Type, DOI
- Authors: George H. Crossley, Prashanthan Sanders, Bert Hansky, Paolo De Filippo, Maully J. Shah, Surinder Kaur Khelae, Travis D. Richardson, François Philippon, John S. Zakaib, Tessa Geelen, Katherin Arias, Baerbel Maus, Pamela K. Mason, for the LEADR Trial Investigators
- Journal: Circulation: Arrhythmia and Electrophysiology 2026;19:e014424
- Affiliations: Vanderbilt University Medical Center (Nashville, TN); Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital (Adelaide, Australia); Städtische Kliniken Bielefeld (Bielefeld, Germany); ASST Papa Giovanni XXIII (Bergamo, Italy); The Children's Hospital of Philadelphia (Philadelphia, PA); Institut Jantung Negara (Kuala Lumpur, Malaysia); Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University (Québec, Canada); Minneapolis Heart Institute Foundation (Minneapolis, MN); Medtronic Bakken Research Center (Maastricht, the Netherlands); Medtronic, Inc (Minneapolis, MN); University of Virginia Medical Center (Charlottesville, VA)
- Type: Global, prospective, multicentre, single-arm, adaptive pivotal clinical trial (NCT04863664)
- DOI: 10.1161/CIRCEP.125.014424
Overview
LEADR is the pivotal trial of the 4.7-F lumenless, single-coil, integrated bipolar OmniaSecure defibrillation lead implanted in standard right ventricular positions. At a mean follow-up of 32.4 months, 643 of 657 patients (97.9%) were successfully implanted; freedom from lead-related major complications was 96.5% at 3 years, appropriate therapy was delivered to 22.3% of patients, antitachycardia pacing efficacy was 75.4%, and inappropriate shocks occurred in 2.7% at 1 year and 5.9% at 3 years. Electrical parameters remained stable, with one lead fracture at 2.3 years. The trial establishes the medium-term durability of the lead platform in the right ventricle but did not test conduction-system placement, which is the subject of the separate LEADR LBBAP trial (sources/leadr-lbbap-primary-hrs-2026; sources/leadr-lbbap-hrs-2025).
Keywords
Cardiac resynchronization therapy; Catheters; Defibrillator; Freedom; Hospitalization
Key Takeaways
Study design and population
- Global, prospective, multicentre, single-arm, adaptive pivotal trial at 45 sites, June 2021 to November 2022; 675 enrolled, 657 underwent an implant attempt, 643 (97.9%) were successfully implanted.
- Mean follow-up 32.4 ± 9.1 months; 26% women; mean age 61.9 ± 12.9 years.
- Device type: single-chamber ICD 35.9%, dual-chamber ICD 40.7%, CRT-D 23.3%.
- Right ventricular positions: low right ventricular septum 33.1%, mid right ventricular septum 31.9%, right ventricular apex 20.1%.
- The protocol allowed only standard right ventricular positions and explicitly excluded conduction-system locations.
Lead description and design
- The OmniaSecure lead is a 4.7-F, single-coil, integrated bipolar (6.1 cm coil), lumenless, catheter-delivered transvenous defibrillation lead with a DF4 connector; it is magnetic resonance imaging conditional.
- It is built on the lumenless SelectSecure SureScan 3830 pacing lead: the stylet lumen is replaced by a fatigue-resistant flexible cable conductor, allowing a smaller diameter without downsizing the defibrillation components.
- Modifications from the 3830 include replacing the ring electrode with a defibrillation coil, adding insulation to the outer coil, and increasing the thickness of the outer tubing insulation.
Defibrillation efficacy
- The primary efficacy objective was met: successful defibrillation at implant exceeded the prespecified 88% threshold.
- Defibrillation testing per protocol was completed in 119 patients; 116 (97.5%) were successfully defibrillated. Of the remaining three, two had at least one successful conversion at 25 J and remained in the study, and one received a non-study lead and exited.
Ambulatory efficacy
- There were 920 ambulatory ventricular tachycardia or ventricular fibrillation episodes in 123 patients who received appropriate therapy.
- Shocks were delivered in 190 episodes in 61 patients and successfully terminated 181 (95.3%); the remaining episodes were terminated by antitachycardia pacing (6), self-terminated (1), or associated with other factors (2).
- There were 826 monomorphic ventricular tachycardia episodes receiving antitachycardia pacing in 96 patients; efficacy was 75.4% (95% CI 67.9–81.6) by generalized estimating equations. Antitachycardia pacing prevented shocks in 81 patients.
- Appropriate therapy was delivered to 10.7% of patients by 1 year and 22.3% by 3 years; at 3 years this included appropriate shock in 11.0% and antitachycardia pacing in 18.6%.
Inappropriate therapy
- There were 60 inappropriate shocks in 32 patients; the rate was 2.7% at 1 year (95% CI 1.7–4.3) and 5.9% at 3 years (95% CI 4.2–8.4).
- Causes were atrial fibrillation or atrial flutter (38 episodes in 16 patients), other supraventricular tachycardia or sinus tachycardia (9 episodes in 7 patients), and T-wave oversensing (5 episodes in 4 patients).
- There were no inappropriate shocks due to P-wave oversensing; four adverse events (0.6%) were related to P-wave oversensing and five (0.8%) to T-wave oversensing.
Safety and reliability
- Freedom from study lead–related major complications was 97.1% at 6 months and 1 year, 96.9% at 2 years, and 96.5% at 3 years (95% CI 94.8–97.7).
- There were 22 major complications in 22 patients (3.3%): lead dislodgement 11 (1.7%), oversensing 5 (0.8%), cardiac perforation 2 (0.3%), device capturing issue 1 (0.2%), lead damage or fracture 1 (0.2%), left ventricular dysfunction 1 (0.2%), and Twiddler syndrome 1 (0.2%). Fourteen occurred within 30 days.
- One lead fracture occurred at 2.3 years, within the predicted range; fracture-free survival was 99.8% at 3 years in the trial and 99.9% in the simulated patient model. The projected 10-year fracture-free rate is 98.2% overall and 97.9% in adolescents.
- Twenty-eight leads were explanted; median dwell time 123.5 days (range 0–777), with 11 explanted within 30 days. The most common reasons were lead dislodgement, heart transplantation and infection.
- There were 63 deaths; none were adjudicated as causally related to the OmniaSecure lead. One death was related to the ICD but not to the lead.
Electrical and sensing performance
- Pacing capture threshold was 0.6 ± 0.3 V at implant and 0.6 ± 0.3 V at 36 months.
- R-wave amplitude was 10.2 ± 4.9 mV at implant, 12.5 ± 5.4 mV at 3 months, and 11.9 ± 5.7 mV at 36 months.
- Pacing impedance was 633 ± 175 Ω at implant, 394 ± 65 Ω at 3 months, and 361 ± 63 Ω at 36 months.
Interpretation
- The lead platform performed well through 3 years in the right ventricle, with stable electrical parameters and a low major-complication rate.
- The 3-year safety and efficacy data support the lead's use in standard right ventricular positions, including in patients with CRT-D.
- The trial did not test left bundle branch area or other conduction-system positions; those data come from the separate LEADR LBBAP trial, whose longest follow-up is shorter.
- The smaller diameter may reduce tricuspid and vascular complications, but the trial was not powered for those endpoints; it showed no adverse events associated with the tricuspid valve that were causally related to the lead.
Limitations of the document
- Single-arm, non-randomised, no control group. The primary objectives used prespecified thresholds based on historical data rather than a concurrent comparator, which may introduce bias.
- Right ventricular placement only. The protocol explicitly excluded conduction-system locations, so the 3-year durability data cannot be extrapolated to left bundle branch area placement.
- Three-year follow-up. Longer-term durability and extraction outcomes remain unknown; a postapproval study (NCT07005232) is ongoing.
- Industry sponsorship. Medtronic funded the trial; several authors are employees, and multiple investigators report consultancy or honoraria.
- Data sharing not available. The data are owned by the sponsor and will not be made available for reproduction.
- Inappropriate shock rate of 5.9% at 3 years — although lower than some historical leads, it remains a clinically relevant harm; the integrated bipolar design carries a risk of T-wave oversensing.
- The trial does not address the case-report question — it provides no data on ventricular tachycardia storm, lead insertion-site arrhythmia, or ablation near the lead.
Key Concepts Mentioned
- entities/ICD — the device platform and lead technology
- concepts/ICD-Programming — antitachycardia pacing and detection
- concepts/Cardiac-Resynchronization-Therapy — the CRT-D subgroup
- concepts/Left-Bundle-Branch-Area-Pacing — the separate trial of the same lead in the LBBA position
- concepts/Conduction-System-Pacing — the broader physiological pacing context
Key Entities Mentioned
- Medtronic — manufacturer and sponsor; OmniaSecure defibrillation lead
- LEADR Trial Investigators — multicentre trial group
- SelectSecure 3830 — the predicate lumenless pacing lead
- Vanderbilt University Medical Center — coordinating centre
Wiki Pages Updated
- Created:
wiki/sources/leadr-final-circep-2026.md - Updated:
wiki/concepts/LBBAP-Outcomes.md - Updated:
wiki/entities/ICD.md - Updated:
wiki/sourceindex.md - Updated:
wiki/wikiindex.md - Updated:
log.md